Abstract
Newly proposed SIQR model defines exponent λ of exponential function expressing daily number of isolated persons as linear equation of isolation rate q and social distancing ratio x. In order to dynamically analyze the process of COVID-19 epidemic in seven countries by means of regression analyses of λ, increasing rate of cumulative isolated persons(cases), IRCC, is proposed as practical index for the isolation rate q. IRCC is correlated with q in the form of q=C · IRCC, where C is a normalizing coefficient. At first, C is formulated in two modes, one is simple and the other complex, under the constraint conditions by definition 0≤x, q≤1, which give allowable narrow path of C between upper and lower boundaries. Then, the dynamic locus of q-x relation is analyzed for each of seven countries including Japan and the United States using formulated isolation rate q, and characteristic q-x behavior for each country is derived. At the same time, it is shown that specific path selection of C gives almost same linear loci of q-x relation derived by mathematical sequential method imitating a bipedal walk. In addition, increasing rates of cumulative PCR tests, IRCT, for six countries are discussed in relation with IRCC, and are shown that IRCT contributes to the promotion of the isolation rate via IRCC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.